Pliant Therapeutics Revenue and Competitors

Claim your profile

Location

#9460

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Pliant Therapeutics's estimated annual revenue is currently $10M per year.(i)
  • Pliant Therapeutics received $62.0M in venture funding in July 2018.
  • Pliant Therapeutics's estimated revenue per employee is $85,812
  • Pliant Therapeutics's total funding is $207.4M.
  • Pliant Therapeutics's current valuation is $457M. (January 2022)

Employee Data

  • Pliant Therapeutics has 117 Employees.(i)
  • Pliant Therapeutics grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$54.7M27235%N/AN/A
#2
$1.2M6N/AN/AN/A
#3
$26.3M1313%N/AN/A
#4
$35M1240%$62.5MN/A
#5
$21.9M10910%N/AN/A
#6
$137.5M684-4%N/AN/A
#7
$14.9M8616%$173MN/A
#8
$91.3M454N/AN/AN/A
#9
$64.5M321-7%N/AN/A
#10
$9.4M470%N/AN/A

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF- modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant's co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

keywords:N/A

$207.4M

Total Funding

117

Number of Employees

$10M

Revenue (est)

18%

Employee Growth %

$457M

Valuation

N/A

Accelerator

Pliant Therapeutics News

2022-04-17 - We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

As at December 2021, Pliant Therapeutics had cash of US$201m and no debt. In the last year, its cash burn was US$77m. So it had a cash runway of...

2022-04-13 - Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus ...

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of “Buy” by Analysts. Posted by admin on Apr 17th, 2022.

2022-04-06 - Read Why Pliant Therapeutics Shares Are Soaring Today - Benzinga

Pliant Therapeutics Inc · Roche Holdings AG's · PLRX believes PLN-74809 can improve upon existing therapies across efficacy and safety/...

2019-09-08 - Orchard Therapeutics Further Strengthens Board of Directors with Appointment of John Curnutte, M.D., Ph.D.

He currently serves on the board of directors of Pliant Therapeutics. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from ...

2019-09-07 - Pliant Therapeutics Reports Positive Results of Phase 1b ...

SOUTH SAN FRANCISCO, June 27, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M12010%$308.6M
#2
$199.8M12449%$333.1M
#3
$19.7M12734%$159.9M
#4
$20M12995%$195.7M
#5
$47.7M13511%N/A

Pliant Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-02-19$45.0MAThird Rock Ventures, LLCArticle
2018-07-17$62.0MBCowen Healthcare InvestmentsArticle